Opioid antagonists are known for their ability to reverse the effects of opioid receptors. They are called receptor antagonists that block the receptors released from opioid intake, preventing the impact of opioids and endorphins on your brain. They are deemed useful in the treatment of opioid overdose and abuse.
However, opioid antagonists are reported to produce enhanced analgesia of opioid agonists. There are three major classifications of opioid receptors- mu, kappa, and delta receptors. These receptors are crucial for pain transmission, modifying pathways of neurotransmission in the midbrain, spinal cord, limbic system, and thalamus. Our body has opioid receptors, including but not limited to our gastrointestinal tract, pituitary gland, immune cells, and skin. Opioid receptors perform analgesic and non-analgesic functions.
Here’s the summary of physiological and pharmacological effects of opioid receptors-
Inhibit dopamine release
Modulation of mu receptor
Central mu receptors cause analgesia, respiratory depression, and euphoria. Peripheral mu are tissue-specific with concentrated in the digestive tract, and bronchial smooth muscle. This causes constipation and cough reflex. Kappa and delta-opioid do have analgesic effects, kappa is known for hallucinations, disassociation, and dysphoria, and delta also modify mu receptors.
How Does it Work?
The two commonly known opioid antagonists are naltrexone and naloxone. Naltrexone is available in both forms- long-acting injectable and oral. Naloxone comes in intramuscular, intravenous and intranasal formulations. Both antagonists are FDA-approved for the treatment of opioid overdose. Naloxone gains spotlight after the need for accessible reversal agents for an acute opioid overdose.
Centrally opioid antagonists are competitive inhibitors and affinity for the mu receptor. Naloxone is commonly used in opioid overdose emergencies, and naltrexone is a very primary choice in alcohol and opioid disorders that help maintain abstinence by decreasing cravings.
An opiate withdrawal caused by naltrexone during a supervised medical treatment or naloxone in the pre-hospital emergency can lead to hospital admission. During a supervised withdrawal, the naltrexone dose is carefully monitored as there’s an increase in dosage, resulting in an opiate washout.
For medical-supervised withdrawal management, the aim is to reduce the body transition to naltrexone, thus reducing patient hospital stays inconvenience and treatment costs. This method is not commonly used.
Usual Administration Regimens for Opioid Antagonists
|Reverse CNS and respiratory depression in suspected narcotic overdose For diagnosis of suspected opioid tolerance or acute opioid overdosage
|Dosage Forms: Injection, as hydrochloride; 0.4 mg/ml (1 ml, 10 mL), IM, IV (preferred), intratracheal, SC. Opioid Overdose-Known or Suspected: I.V.: 0.4–2 mg every 2–3 minutes as needed, if no response is observed after 10 mg, question the diagnosis. IM or SC administration may be necessary if the IV route is not available. Postoperative Respiratory Depression: In increments of 0.1–0.2 mg intravenously at 2 ∼3 minute intervals to the desired degree of reversal (i.e. adequate ventilation and alertness without significant pain or discomfort) Repeat doses may be required within 1 ∼ 2 hour intervals depending upon the opioid amount, type (i.e., short or long-acting) and time interval since last administration. Supplemental intramuscular doses have been shown to produce a longer-lasting effect.
|Adjunct to the maintenance of an opioid-free state in a detoxified individual.
|Dosage forms: Tablet, as hydrochloride: 50 mg. Do not give until patient is opioid-free for 7 ∼10 days as determined by urine analysis: Oral: 25 mg; if no withdrawal signs within 1 hour give another 25 mg; maintenance regimen is flexible, variable and individualized (50 mg/day to 100 ∼150 mg 3 times/week).
|Oral nalmefene has undergone preliminary investigation in several conditions, including interstitial cystitis, and may be a useful alternative to naltrexone for the management of opioid addiction.
|Dosage form: Solution for injection; 100 μg/ml (1 ml) for postoperative use, 1 mg/1ml (2 ml) for opioid overdose; IM, IV (preferred), SC, oral. Opioid overdose: 0.5 mg/70 kg IV. If needed, give a second dose of 1 mg/70 kg, 2 ∼ 5 minutes later. Max cumulative dose 1.5 mg/70 kg; if suspicion of opioid dependency, initial dose of 0.1 mg/70 kg is recommended. If there is no evidence of withdrawal symptoms within 2 minutes, the usual dosage may be used; 0.5 or 1 mg IV bolus injection is also effective. Postoperative respiratory depression: 0.25 μg/kg IV, repeat at 2 ∼ 5 min intervals prn. Max cumulative dose 1 μg/kg.
The above table concludes how opioid antagonists are used to reversing opioid overdosages or life-threatening opioid toxicity. Patients dependent on opioids may witness an abrupt reversal of opioid effects during acute withdrawal syndrome. The usual dosage of antagonists can trigger severe pain in a palliative care patient.
For less severe toxicity in patients with chronic pain, lower antagonist formulations should be utilized and monitored. For example, a terminally ill patient will respiratory sedation or depression, instead of naloxone 1 ampule, a quarter of an ampule or less can be given after every 15 minutes up until a clinician see the desired result.
For the treatment of opioid-related side effects related to fentanyl or epidural morphine, naloxone and nalbuphine are used to decrease the occurrence of respiratory depression, vomiting, and pruritus.
Recent clinical studies have found that co-treatment with low doses of opioid antagonists can reduce the side effects of morphine and related opioid analgesics and lessen the development of tolerance.
The administered opioid antagonist has gained widespread awareness in a reversal of opioid toxicity and countering side effects connected with spinally administered opioids. For palliative care, low dosages should be monitor in a partial or complete reversal of opioid. Orally administered antagonists have played a role in the management of not only of opioid abstinence but also for alcohol abuse. A new antagonist, Methylnaltrexone, works on peripheral opioid receptors that are clinically used in the treatment of opioid-induced side effects without affecting analgesia or with fewer adverse effects.